Stock Track | Wave Life Sciences Plummets 5.08% on Concerns Over Increased Expenses Despite Revenue Boost

Stock Track

2025/03/06

Wave Life Sciences (WVE) stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.

The biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.

Research and development expenses soared to $44.6 million in Q4 2024, primarily due to increased spending on Wave's INHBE, AATD, and DMD programs. General and administrative expenses also rose to $16.1 million during the same period. Despite the revenue boost, Wave Life Sciences reported a net loss of $96.7 million for the full year 2024, indicating ongoing financial challenges.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1159360000"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159360000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159360000?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-06 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159360000","market":"us","top_or_hot":-1,"title":"Stock Track | Wave Life Sciences Plummets 5.08% on Concerns Over Increased Expenses Despite Revenue Boost","media":"Stock Track","content":"<p>Wave Life Sciences (WVE) stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.</p>\n\n<p>The biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.</p>\n\n<p>Research and development expenses soared to $44.6 million in Q4 2024, primarily due to increased spending on Wave's INHBE, AATD, and DMD programs. General and administrative expenses also rose to $16.1 million during the same period. Despite the revenue boost, Wave Life Sciences reported a net loss of $96.7 million for the full year 2024, indicating ongoing financial challenges.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Wave Life Sciences Plummets 5.08% on Concerns Over Increased Expenses Despite Revenue Boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Wave Life Sciences Plummets 5.08% on Concerns Over Increased Expenses Despite Revenue Boost\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-03-06 00:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Wave Life Sciences (WVE) stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.</p>\n\n<p>The biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.</p>\n\n<p>Research and development expenses soared to $44.6 million in Q4 2024, primarily due to increased spending on Wave's INHBE, AATD, and DMD programs. General and administrative expenses also rose to $16.1 million during the same period. Despite the revenue boost, Wave Life Sciences reported a net loss of $96.7 million for the full year 2024, indicating ongoing financial challenges.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"","article_id":"1159360000","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159360000","pubTimestamp":1741193306,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Wave Life Sciences  stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.The biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.Research and de","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"尽管收入增加，但由于对费用增加的担忧，Wave Life Sciences股价暴跌5.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1},"content_text":"Wave Life Sciences (WVE) stock plummeted 5.08% on Wednesday in the intraday trading session, despite reporting a significant revenue surge in its Q4 2024 earnings.\nThe biotechnology company, focused on developing RNA medicines, saw its revenue climb to $83.7 million in Q4 2024, up from the previous quarter. This was driven by recognition of deferred revenue from its collaboration with Decata. However, the company's expenses also increased substantially, raising concerns among investors.\nResearch and development expenses soared to $44.6 million in Q4 2024, primarily due to increased spending on Wave's INHBE, AATD, and DMD programs. General and administrative expenses also rose to $16.1 million during the same period. Despite the revenue boost, Wave Life Sciences reported a net loss of $96.7 million for the full year 2024, indicating ongoing financial challenges.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}